CHF
MCID: CNG034
MIFTS: 71

Congestive Heart Failure (CHF)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Congestive Heart Failure

MalaCards integrated aliases for Congestive Heart Failure:

Name: Congestive Heart Failure 39 12 77 30 6 15 17 74
Heart Failure 45 74 64
Cardiac Failure Congestive 12
Congestive Heart Disease 12
Heart Failure Congestive 56
Weak Heart 12
Chf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6000
ICD9CM 36 428 428.0 428.9
MeSH 45 D006333
NCIt 51 C3080 C50577
SNOMED-CT 69 42343007 84114007

Summaries for Congestive Heart Failure

PubMed Health : 64 About heart failure: Heart failure is a condition in which the heart can't pump enough blood to meet the body's needs. In some cases, the heart can't fill with enough blood. In other cases, the heart can't pump blood to the rest of the body with enough force. Some people have both problems.The term "heart failure" doesn't mean that your heart has stopped or is about to stop working. However, heart failure is a serious condition that requires medical care.

MalaCards based summary : Congestive Heart Failure, also known as heart failure, is related to pulmonary edema and orthostatic intolerance, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Congestive Heart Failure is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and Dilated cardiomyopathy (DCM). The drugs Sodium Citrate and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include Adipose and Lateral Plate Mesoderm, and related phenotype is muscle.

Disease Ontology : 12 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.

Wikipedia : 77 Heart failure (HF), also known as chronic heart failure (CHF), is when the heart is unable to pump... more...

Related Diseases for Congestive Heart Failure

Diseases related to Congestive Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 879)
# Related Disease Score Top Affiliating Genes
1 pulmonary edema 32.7 ACE EDN1 NPPA NPPB REN
2 orthostatic intolerance 32.7 ADRB1 ADRB2 EDN1
3 cardiac arrest 32.6 ACE MYH7 NPPB
4 pulmonary hypertension, primary, 1 32.5 EDN1 NPPA NPPB
5 heart disease 32.4 ACE ADRB1 EDN1 HOTAIR MYH6 MYH7
6 atrial fibrillation 31.9 ACE ADRB1 NPPA NPPB
7 hypoaldosteronism 31.9 ACE NPPA REN
8 sleep apnea 31.6 ACE EDN1 NPPB REN
9 arteries, anomalies of 31.4 ACE EDN1 NPPB REN
10 mitral valve insufficiency 31.4 ACE NPPA NPPB
11 central sleep apnea 31.4 NPPA NPPB
12 chronic kidney failure 31.2 ACE EDN1 NPPA NPPB REN
13 kidney disease 31.2 ACE EDN1 NPPA NPPB REN
14 coronary artery anomaly 31.2 ACE ADRB1 ADRB2 EDN1 NPPA NPPB
15 angina pectoris 31.0 ACE EDN1 NPPB
16 aortic coarctation 31.0 ACE ADRB1 ADRB2 EDN1
17 dilated cardiomyopathy 31.0 ACE ADRB1 ADRB2 EDN1 MYH6 MYH7
18 pulmonary hypertension 30.9 ACE EDN1 MIR21 NPPA NPPB REN
19 atrial standstill 1 30.9 ACE ADRB1 MYH6 MYH7 NPPB
20 pericardial effusion 30.9 NPPA NPPB REN
21 diastolic heart failure 30.9 ACE NPPA NPPB
22 coronary heart disease 1 30.8 ACE ADRB1 CDKN2B-AS1 NPPB
23 tetralogy of fallot 30.8 EDN1 NPPA NPPB REN
24 acute myocardial infarction 30.8 ACE ADRB1 CDKN2B-AS1 EDN1 MHRT NPPA
25 chagas disease 30.8 ACE ADRB1 NPPB
26 aortic valve disease 2 30.7 ACE MYH7 NPPA NPPB REN
27 pure autonomic failure 30.7 ACE NPPA REN
28 resting heart rate, variation in 30.7 ADRB1 ADRB2
29 renovascular hypertension 30.6 ACE EDN1 NPPA REN
30 liver cirrhosis 30.6 EDN1 HOTAIR NPPA REN
31 myocardial infarction 30.6 ACE ADRB1 ADRB2 CDKN2B-AS1 EDN1 MIR21
32 muscle hypertrophy 30.5 EDN1 MYH6 MYH7 NPPA
33 syndrome of inappropriate antidiuretic hormone 30.5 ACE NPPA NPPB
34 renal artery disease 30.4 ACE REN
35 renal hypertension 30.4 ACE EDN1 NPPB REN
36 systolic heart failure 30.4 ACE ADRB1 EDN1 NPPB
37 aortic valve disease 1 30.4 ACE NPPB REN
38 pre-eclampsia 30.3 EDN1 HOTAIR NPPA REN
39 hypoplastic left heart syndrome 30.2 MYH6 NPPA NPPB
40 autosomal dominant polycystic kidney disease 30.1 ACE EDN1 REN
41 hypertensive retinopathy 30.0 ACE REN
42 cerebrovascular disease 30.0 ACE HOTAIR REN
43 hepatorenal syndrome 30.0 ACE EDN1 NPPA REN
44 hypertension, essential 29.9 ACE ADRB1 ADRB2 CDKN2B-AS1 EDN1 NPPA
45 vascular disease 29.7 ACE EDN1 MIR21 MIR214 REN
46 polymyositis 29.3 MIR21 MIR214
47 osteogenic sarcoma 29.2 CDKN2B-AS1 HOTAIR TUSC7
48 ovarian cancer 28.4 BACE1-AS CDKN2B-AS1 HOTAIR MIR195 MIR21 MIR214
49 hepatocellular carcinoma 27.4 CDKN2B-AS1 HOTAIR MIR195 MIR21 MIR214 MIR23A
50 polycystic kidney disease 4 with or without polycystic liver disease 11.9

Graphical network of the top 20 diseases related to Congestive Heart Failure:



Diseases related to Congestive Heart Failure

Symptoms & Phenotypes for Congestive Heart Failure

UMLS symptoms related to Congestive Heart Failure:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Congestive Heart Failure:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.17 ADRB1 ADRB2 EDN1 MYH6 MYH7 NPPA

Drugs & Therapeutics for Congestive Heart Failure

PubMedHealth treatment related to Congestive Heart Failure: 64

Early diagnosis and treatment can help people who have heart failure live longer, more active lives. Treatment for heart failure will depend on the type and stage of heart failure (the severity of the condition).The goals of treatment for all stages of heart failure include:Treating the condition's underlying cause, such as coronary heart disease (CHD), high blood pressure, or diabetesReducing symptomsStopping the heart failure from getting worseIncreasing your lifespan and improving your quality of lifeTreatments usually include lifestyle changes, medicines, and ongoing care. If you have severe heart failure, you also may need medical procedures or surgery.

Drugs for Congestive Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68-04-2
2
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-31-9 3440
3
Metolazone Approved Phase 4,Phase 3,Phase 1,Not Applicable 17560-51-9 4170
4
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
5
Dobutamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34368-04-2 36811
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
7
Digoxin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 20830-75-5 30322 2724385
8
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-01-7, 1952-01-7 5833
9
Verapamil Approved Phase 4,Phase 3,Not Applicable 52-53-9 2520
10
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72956-09-3 2585
11
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 114798-26-4 3961
12
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83915-83-7, 76547-98-3 5362119
13
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
14
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
17
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
18
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-78-2 2244
19
Terbutaline Approved Phase 4,Not Applicable 23031-25-6 5403
20
Ipratropium Approved Phase 4,Phase 3 60205-81-4, 22254-24-6 43232 657309
21
Fluticasone Approved, Experimental Phase 4,Phase 3 90566-53-3 62924
22
Budesonide Approved Phase 4,Phase 3 51333-22-3 63006 5281004
23
Enalaprilat Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 76420-72-9 6917719
24
Enalapril Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 75847-73-3 5362032 40466924
25
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
26
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
27
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
28
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 104987-11-3 445643 439492 6473866
29
Captopril Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 62571-86-2 44093
30
Nebivolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 118457-14-0, 99200-09-6, 152520-56-4 71301
31
Eplerenone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107724-20-9 150310 443872
32
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
33
Bisoprolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 66722-44-9 2405
34
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1 145040-37-5 2540
35
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
36
Tirofiban Approved Phase 4,Not Applicable 144494-65-5 60947
37
Tenecteplase Approved Phase 4,Phase 3,Phase 2,Not Applicable 191588-94-0
38
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-24-7, 144689-63-4 130881 158781
39
Telmisartan Approved, Investigational Phase 4,Phase 2,Phase 3 144701-48-4 65999
40
Pentoxifylline Approved, Investigational Phase 4,Not Applicable 6493-05-6 4740
41
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
42
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
43
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
44
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
45
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
46
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 171596-29-5 110635
47
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
48
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
49
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
50
Gliclazide Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 21187-98-4 3475

Interventional clinical trials:

(show top 50) (show all 6562)
# Name Status NCT ID Phase Drugs
1 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
2 Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
3 Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
4 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
5 THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
6 PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing Unknown status NCT00409916 Phase 4
7 Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline
8 Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
9 A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL) Unknown status NCT00247000 Phase 4
10 Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
11 Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Unknown status NCT00541268 Phase 4
12 Improvement of Patients With Chronic Heart Failure Using NT-proBNP Unknown status NCT00601679 Phase 4
13 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
14 Inspiratory Muscle Training Effectiveness in Sympathetic Activity and Functional Capacity in Patients With Heart Failure Unknown status NCT02600000 Phase 4
15 Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
16 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4 Levosimendan in addition to standard therapy;spironolactone, beta-blockers,ecc
17 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
18 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
19 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure Unknown status NCT01156207 Phase 4 Aliskiren
20 Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
21 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
22 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
23 Remission From Stage D Heart Failure Unknown status NCT01774656 Phase 4 Pharmacological Treatment
24 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
25 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
26 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
27 Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication Unknown status NCT01415024 Phase 4
28 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
29 Body Composition Measurements in Chronic Heart Failure Unknown status NCT02686866 Phase 4
30 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
31 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. Unknown status NCT02963597 Phase 4
32 Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
33 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
34 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
35 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
36 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
37 Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial Unknown status NCT02454439 Phase 4
38 Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human Unknown status NCT01069042 Phase 4 Enalapril
39 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
40 Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
41 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
42 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
43 Saxagliptin and Cardiac Structure and Function Unknown status NCT02481479 Phase 4 Saxagliptin;Saxagliptin;saxagliptin
44 Once-a-day Tacrolimus Conversion Study: The OneTAC Trial Unknown status NCT02545972 Phase 4 tacrolimus extended release
45 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
46 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
47 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
48 Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Unknown status NCT02200822 Phase 4 beta blockers;RAAS blockers
49 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
50 Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin

Search NIH Clinical Center for Congestive Heart Failure

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Congestive Heart Failure cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Congestive Heart Failure:
ACP-01, autologous angiogenic precursor cells for cardiac diseases
Adipose-derived stem cells for treatment of congestive heart failure
BMAC�, autologous bone marrow aspirate concentrate for congestive heart failure
Bone marrow-derived adult mononuclear cells for heart diseases
Cardiac progenitor cells for single-ventricle anomalies
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
C-Cure�, mesenchymal stem cell-derived cardiomyocytes for heart failure
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
CD34+ stem cells for treatment of congestive heart failure
Enriched bone marrow-derived progenitor cells for heart diseases
ERCs, endometrial regenerative cells for congestive heart failure
Human cardiac-derived stem cell for the treatment of congestive heart failure
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
MyoCell�, muscle stem cells for severe heart damage
Peripheral or bone marrow-derived stem cells for chronic heart failure
Embryonic/Adult Cultured Cells Related to Congestive Heart Failure:
Angiogenic cell precursors
Adipose-derived mesenchymal stem cells (family)
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 23788089 18351022
Bone marrow-derived mononuclear cells PMIDs: 22137069 19699857 20445812 20524773
Cardiac stem cells PMIDs: 18754813 17502484 14530411
Cardiac progenitor cells PMIDs: 18754813 17502484 14530411
Cardiosphere-derived cells PMIDs: 22336189
Cardiomyocyte-like cells PMIDs: 23583247 18835562
Bone marrow-derived CD133+ cells PMIDs: 17320570
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120
Bone marrow-derived progenitor cells PMIDs: 23362308 22936827 18794392 16990384 16990385 22651868
Endometrial regenerative cells PMIDs: 18005405 23510656 20398245 19232091
Human cardiac stem cells PMIDs: 17502484 19038683 17150190
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Skeletal myoblasts (MyoCell�) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mononuclear cells PMIDs: 20668107 21596713 19761394 22834565

Cochrane evidence based reviews: heart failure

Genetic Tests for Congestive Heart Failure

Genetic tests related to Congestive Heart Failure:

# Genetic test Affiliating Genes
1 Congestive Heart Failure 30

Anatomical Context for Congestive Heart Failure

MalaCards organs/tissues related to Congestive Heart Failure:

42
Heart, Kidney, Breast, Lung, Testes, Bone, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Congestive Heart Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
2 Lateral Plate Mesoderm Splanchnic Mesoderm Pericytes Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Congestive Heart Failure

Articles related to Congestive Heart Failure:

(show top 50) (show all 6357)
# Title Authors Year
1
Predictive value of blood urea nitrogen/creatinine ratio in the long-term prognosis of patients with acute myocardial infarction complicated with acute heart failure. ( 30882678 )
2019
2
Re: Association of the Hospital Readmissions Reduction Program with Mortality among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. ( 30888900 )
2019
3
Increased Serum CA125 and Brain-Derived Neurotrophic Factor (BDNF) Levels on Acute Myocardial Infarction: A Predictor for Acute Heart Failure. ( 30706901 )
2019
4
Readmission and mortality in patients ≥70 years with acute myocardial infarction or heart failure in the Netherlands: a retrospective cohort study of incidences and changes in risk factors over time. ( 30715672 )
2019
5
Serum Circulating miR-150 is a Predictor of Post-Acute Myocardial Infarction Heart Failure. ( 30745540 )
2019
6
Relationship Between Patient-Reported Hospital Experience and 30-Day Mortality and Readmission Rates for Acute Myocardial Infarction, Heart Failure, and Pneumonia. ( 30746641 )
2019
7
Understanding the role of echocardiography in remodeling after acute myocardial infarction and development of heart failure with preserved ejection fraction. ( 30779834 )
2019
8
Ischemic heart failure as a complication of incident acute myocardial infarction: Timing and time trends: A national analysis including 78,814 Danish patients during 2000-2009. ( 30813840 )
2019
9
Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. ( 30578576 )
2019
10
Gender disparities among hospitalised patients with acute myocardial infarction, acute decompensated heart failure or pneumonia: retrospective cohort study. ( 30670508 )
2019
11
Activin type II receptor signaling in cardiac aging and heart failure. ( 30842316 )
2019
12
Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio, leading to inflamed milieu in acute heart failure. ( 30768364 )
2019
13
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. ( 30753432 )
2019
14
Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. ( 30649240 )
2019
15
Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure. ( 30718069 )
2019
16
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. ( 30833839 )
2019
17
Does heart failure-specific health status identify patients with bothersome symptoms, depression, anxiety and/or poorer spiritual well-being? ( 30649237 )
2019
18
Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. ( 30765282 )
2019
19
High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia. ( 30790397 )
2019
20
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. ( 30792887 )
2019
21
Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. ( 30413926 )
2019
22
Medicaid Expansion and Mechanical Ventilation in Asthma, Chronic Obstructive Pulmonary Disease, and Heart Failure. ( 30811951 )
2019
23
Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis. ( 30314929 )
2019
24
A 79-year-old woman with atrial fibrillation and new onset of heart failure. ( 30903653 )
2019
25
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. ( 30908512 )
2019
26
Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. ( 30910388 )
2019
27
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. ( 30912456 )
2019
28
Exchange-protein activated by cAMP (EPAC) regulates L-type calcium channel in atrial fibrillation of heart failure model. ( 30915767 )
2019
29
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. ( 30871349 )
2019
30
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model. ( 30874892 )
2019
31
Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). ( 30876658 )
2019
32
Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. ( 30887281 )
2019
33
Procedural Outcomes of Patients With Heart Failure Undergoing Catheter Ablation of Atrial Fibrillation. ( 30893071 )
2019
34
Managements and Outcomes of Hospitalized Heart Failure Patients with Paroxysmal vs. Nonparoxysmal Atrial Fibrillation in Taiwan. ( 30893259 )
2019
35
Case of a patient with heart failure, dilated cardiomyopathy, and atrial fibrillation treated with sacubitril/valsartan. ( 30895821 )
2019
36
Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. ( 30896056 )
2019
37
What Have We Learned From Randomized Controlled Trials of Catheter Ablation for Atrial Fibrillation in Patients With Chronic Heart Failure? ( 30897965 )
2019
38
Relationship between the CHA2DS2VASc score and the occurrence of atrial fibrillation in patients hospitalised due to heart failure. ( 30835325 )
2019
39
Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. ( 30838721 )
2019
40
Catheter Ablation for Atrial Fibrillation in Heart Failure: Ready for Mainstream Adoption, or Is More Evidence Needed? ( 30846417 )
2019
41
Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure? ( 30847508 )
2019
42
Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. ( 30788620 )
2019
43
Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control. ( 30790104 )
2019
44
Association between atrial fibrillation and right-sided manifestations of congestive heart failure in dogs with degenerative mitral valve disease or dilated cardiomyopathy. ( 30797441 )
2019
45
The impact of catheter ablation for atrial fibrillation in heart failure. ( 30805042 )
2019
46
Atrial fibrillation among adults with heart failure in sub-Saharan Africa - prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. ( 30808667 )
2019
47
Burden of Implanted-Device-Detected Atrial High-Rate Episode Is Associated With Future Heart Failure Events - Clinical Significance of Asymptomatic Atrial Fibrillation in Patients With Implantable Cardiac Electronic Devices. ( 30814400 )
2019
48
Ethnicity, heart failure, atrial fibrillation and diabetes: collider bias. ( 30728157 )
2019
49
Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. ( 30661038 )
2019
50
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment. ( 30663127 )
2019